HannyTobanAl-SamkariMD(He/Him)

Clotting Disorder, Hemophilia & Bleeding Disorder, Sickle Cell & Other Anemias

Classical Hematologist and Clinical Investigator; Co-Director, MGH Hereditary Hemorrhagic Telangiectasia Center of Excellence

Dr. Al-Samkari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Hanny Al-Samkari, M.D. is an Associate Professor of Medicine at Harvard Medical School as well as an NIH- and U.S. DOD-funded clinical investigator and classical hematologist at the Massachusetts General Hospital (MGH) Division of Hematology Oncology. He also serves as Co-Director the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. His clinical and research interests are in hemostasis, thrombosis and hemolysis, with focuses in HHT, immune thrombocytopenia and other thrombocytopenias, and hereditary hemolytic anemias. He currently serves as PI for many clinical trials in these areas and is an internationally-recognized expert in the clinical development of novel therapeutics for HHT, hemolytic anemias and thrombocytopenias. He is the current Executive Editor of Hematology: The ASH Education Program, an American Society of Hematology peer-reviewed publication, and has published over 130 peer-reviewed manuscripts. His original research has been featured in The New England Journal of Medicine, The Lancet, and Blood, among other top peer-reviewed journals in hematology and medicine.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2018
University of Pennsylvania Health SystemChief Residency, Internal Medicine, 2014 - 2015
University of Pennsylvania Health SystemResidency, Internal Medicine, 2011 - 2014
Washington University in St. Louis School of MedicineClass of 2011

PubMed

Abstracts/Posters

Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia
Hanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/2019
Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency
Hanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency
Hanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National U.S. Survey
Hanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Serum Complement Levels in Immune Thrombocytopenia: Characterization and Relation to Clinical Features
Hanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Training Program DirectorsÍ Workshop
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bl...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Training Program DirectorsÍ Workshop
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Antiplatelet Antibody Testing in Immune Thrombocytopenia and Evans Syndrome: Longitudinal Serologic Evolution and Relation to Clinical Features
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Pomalidomide Efficacious in Hereditary Hemorrhagic TelangiectasiaSeptember 24th, 2024
Clinical Trial Successfully Repurposes Cancer Drug for Hereditary Bleeding DisorderSeptember 18th, 2024
Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHTAugust 27th, 2024
Join now to see all